{'fraction_non_alphanumeric': 0.0288659793814433, 'fraction_numerical': 0.018556701030927835, 'mean_word_length': 5.845070422535211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding

The endocannabinoid system is an important modulatory system in the brain. Complex interactions with brain dopaminergic circuits have been demonstrated. The aim of this study was to investigate the in vivo effect of the commonly used antiparkinsonian drugs, levodopa (L‐DOPA) and bromocriptine, on type 1 cannabinoid (CB1) receptors, using the PET radioligand [18F]MK‐9470.